Skip to main content
OpenTrials
Completed

NCT Number: NCT01111357

Study of Human Leukocyte Antigen (HLA) Polymorphisms in Patients With Rheumatoid Arthritis

Rheumatoid arthritis (RA), affects between 0.3% and 1.0% of the population, it can lead to progressive joint destruction and severe disability. To date, two RA genetic susceptibility factors have been identified: HLA-DRB1-SE (Shared epitope) and PTPN22 620W alleles. The predictive value of the alleles for diagnosis of RA was previously investigated in cohorts of caucasians patients with early unclassified arthritis that showed restrained association between RA and HLA-SE. Despite the contribution of HLA to the overall genetic risk has been estimated to range from 30% to 50%, it has never been studied in the French west-Indian population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service de rhumatologie CHU de Fort-de-France

Fort-de-France, 97261, Martinique

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of Rheumatoid Arthritis according to ACR criteria
  • Come from French West Indies (At least 3 grandparents are African-Caribbean)
  • Sign written informed consent

Exclusion criteria

  • Minor
  • Patient with no Rheumatoid Arthritis according to ACR criteria
  • Patient does not agree for a genetic study

For the control

Inclusion criteria

  • Blood donor
  • Sign written informed consent
  • Patient with no Rheumatoid Arthritis according to ACR criteria
  • Come from French West Indies (At least 3 grandparents are African-Caribbean)

Exclusion criteria

  • Minor
  • Patient does not agree for a genetic study

Treatment and study plan

Collect of 10 ml of peripheric blood for DNA extraction

Biological

After signed written consent, all patients have a clinic exam in order to assess the presence of eligibility criteria (Patient with Rheumatoid Arthritis that fulfil the ACR criteria of diagnosis)

Other names: Rheumatoid Arthritis, French West-Indian Patients with Rheumatoid Arthritis

Primary outcomes

  1. Difference of distribution of HLA alleles in patients and in healthy controls

    Time frame: 1 day

Secondary outcomes

  1. The association between the different HLA alleles among French West-Indian RA patients and the autoantibodies production.

    Time frame: 1 day

  2. The association between the different HLA alleles among French West-Indian RA patients and the radiological damage.

    Time frame: 1 day

  3. The association between the different HLA alleles among French West-Indian RA patients and the response to therapy

    Time frame: 1 day

Sponsors and collaborators

Lead sponsor

University Hospital Center of Martinique

Other

Registry information

Official study title

Study of HLA Polymorphisms in French West-Indian Patients With Rheumatoid Arthritis : A Case Control Study

Acronym: HLAPRPA

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Apr 27, 2010
Registry last updated
Dec 21, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.